Title:
COMPOSITION CONTAINING BACTERIUM BELONGING TO GENUS BIFIDOBACTERIUM AS ACTIVE INGREDIENT
Document Type and Number:
WIPO Patent Application WO/2019/117212
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing: a composition for preventing the adsorption of a bacterium belonging to the genus Fusobacterium to a mucosal cell; and a pharmaceutical composition and a food or beverage composition for preventing or treating a disease or condition that is associated with the inflammation of a mucosal cell and is selected from the group consisting of ulcerative colitis, colorectal cancer, esophagus cancer, premature birth and periodontal disease. The problem can be solved by: a composition for preventing the adsorption of a bacterium belonging to the genus Fusobacterium to a mucosal cell, which contains a bacterium belonging to the genus Bifidobacterium as an active ingredient; and a pharmaceutical composition and a food or beverage composition for preventing or treating a disease or condition that is associated with the inflammation of a mucosal cell and is selected from the group consisting of ulcerative colitis, colorectal cancer, esophagus cancer, premature birth and periodontal disease, which contains a bacterium belonging to the genus Bifidobacterium as an active ingredient.
Inventors:
YOSHIMOTO SHIN (JP)
ODAMAKI TOSHITAKA (JP)
ODAMAKI TOSHITAKA (JP)
Application Number:
PCT/JP2018/045755
Publication Date:
June 20, 2019
Filing Date:
December 12, 2018
Export Citation:
Assignee:
MORINAGA MILK INDUSTRY CO LTD (JP)
International Classes:
A61K35/745; A23L33/135; A61P1/02; A61P1/04; A61P15/06; A61P29/00; A61P31/04; A61P35/00; C12N1/20
Domestic Patent References:
| WO2016194692A1 | 2016-12-08 |
Foreign References:
| JPH07126177A | 1995-05-16 | |||
| JP2003171292A | 2003-06-17 | |||
| JP2013201912A | 2013-10-07 | |||
| JP2012520325A | 2012-09-06 | |||
| JP2017088540A | 2017-05-25 | |||
| JP2012158568A | 2012-08-23 | |||
| JP2016192950A | 2016-11-17 |
Other References:
LEE, D. K. ET AL.: "Antimicrobial activity of Bifidobacterium spp. isolated from healthy adult Korean s against cariogenic microflora", ARCH ORAL BIOL, vol. 56, no. 10, 2011, pages 1047 - 54, XP028304522, ISSN: 0003-9969, doi:10.1016/j.archoralbio.2011.03.002
TAMAKI, H. ET AL.: "Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial .", DIGESTIVE ENDOSCOPY, vol. 28, no. 1, 29 September 2015 (2015-09-29) - January 2016 (2016-01-01), pages 67 - 74, XP055617173, ISSN: 0915-5635
REDDY, B. S.: "Possible Mechanisms by Which Pro- and Prebiotics Influence Colon Carcinogenesis and Tumor Growth", J NUTR, vol. 129, 1999, pages 1478S - 82S, XP002212922, ISSN: 0022-3166
SATISH KUMAR, C. S. ET AL.: "Immunomodulatory effects of Bifidobacterium bifidum 231 on trinitrobenzenesulfonic acid-induced ulcerative colitis in rats.", RES VET SCI, vol. 110, February 2017 (2017-02-01), pages 40 - 6, XP029904775, ISSN: 0034-5288, doi:10.1016/j.rvsc.2016.10.010
JAVED, N. H. ET AL.: "Oral Feeding of Probiotic Bifidobacterium infantis: Colonic Morphological Changes in Rat Model of TNBS-induced Colitis.", SCIENTIFICA, vol. 2016, 2016, pages 1 - 11, XP055617177, ISSN: 2090-908X
JOURNAL OF INTESTINAL MICROBIOLOGY, vol. 27, 2013, pages 169 - 179
CELL HOST MICROBE, vol. 20, 2016, pages 215 - 225
CLIN. CANCER RES., vol. 22, no. 22, 2016
INFECT. IMMUN., vol. 83, no. 3, 2015, pages 1104 - 13
HEALTH PROMOTION ACT, 31 August 2009 (2009-08-31)
See also references of EP 3725321A4
TAMAKI, H. ET AL.: "Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial .", DIGESTIVE ENDOSCOPY, vol. 28, no. 1, 29 September 2015 (2015-09-29) - January 2016 (2016-01-01), pages 67 - 74, XP055617173, ISSN: 0915-5635
REDDY, B. S.: "Possible Mechanisms by Which Pro- and Prebiotics Influence Colon Carcinogenesis and Tumor Growth", J NUTR, vol. 129, 1999, pages 1478S - 82S, XP002212922, ISSN: 0022-3166
SATISH KUMAR, C. S. ET AL.: "Immunomodulatory effects of Bifidobacterium bifidum 231 on trinitrobenzenesulfonic acid-induced ulcerative colitis in rats.", RES VET SCI, vol. 110, February 2017 (2017-02-01), pages 40 - 6, XP029904775, ISSN: 0034-5288, doi:10.1016/j.rvsc.2016.10.010
JAVED, N. H. ET AL.: "Oral Feeding of Probiotic Bifidobacterium infantis: Colonic Morphological Changes in Rat Model of TNBS-induced Colitis.", SCIENTIFICA, vol. 2016, 2016, pages 1 - 11, XP055617177, ISSN: 2090-908X
JOURNAL OF INTESTINAL MICROBIOLOGY, vol. 27, 2013, pages 169 - 179
CELL HOST MICROBE, vol. 20, 2016, pages 215 - 225
CLIN. CANCER RES., vol. 22, no. 22, 2016
INFECT. IMMUN., vol. 83, no. 3, 2015, pages 1104 - 13
HEALTH PROMOTION ACT, 31 August 2009 (2009-08-31)
See also references of EP 3725321A4
Attorney, Agent or Firm:
IP FIRM SHUWA (JP)
Download PDF: